Back

Bleeding risks with frailty and multimorbidity in patients with atrial fibrillation. A nationwide analysis of 1.4 million subjects

29 August 2020 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Oral Anticoagulant Therapy in the Elderly with Atrial Fibrillation Clinical ESC Premium Access ESC Congress 2020

About the speaker

Photo
Professor Laurent Fauchier

University Hospital of Tours, Tours (France)

5 More presentations in this session

Presentation thumbnail
Real-world effectiveness and the safety of anticoagulant treatment in elderly non-valvular atrial fibrillation in the ANAFIE registry, the largest real-world elderly AF registry
Doctor T. Yamashita (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Edoxaban treatment of elderly patients with atrial fibrillation in routine clinical practice: 1-year results of the non-interventional Global ETNA-AF program
Doctor T. Yamashita (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Comparison of warfarin, dabigatran, rivaroxaban and apixaban for effectiveness and safety among elderly patients with atrial fibrillation: a nationwide cohort study
Doctor O. Rutherford (Sarpsborg, NO)
Abstract Slides Video
Presentation thumbnail
Oral anticoagulants in extremely high risk very elderly (>90 years) patients with Atrial Fibrillation
Doctor T. Chao (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
Clinical implications of assessment of apixaban levels in elderly atrial fibrillation patients: J-ELD AF Registry sub-cohort analysis
Doctor S. Suzuki (Tokyo, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Oral Anticoagulant Therapy in the Elderly with Atrial Fibrillation

The Event

Event poster

ESC Congress 2020

29 August - 1 September 2020
You may be interested in
thumbnail
Congress Presentation
Interactive discussion and Q&A
thumbnail
Congress Presentation
Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - discussion
thumbnail
Congress Presentation
Oral anticoagulation in subclinical atrial fibrillation: pro

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources